Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Rigel Shares Plunge After Asthma Drug Fails to Meet Goals

Aug. 26 (Bloomberg) -- Rigel Pharmaceuticals Inc. dropped to its lowest price in almost 13 years after the drugmaker said an experimental treatment for allergic asthma failed in a study.

Rigel declined 14 percent to $3.14 at 4 p.m. New York time, the lowest price since the shares began trading in November 2000. South San Francisco-based Rigel has fallen 68 percent in the last 12 months.

The inhaled drug, R343, didn’t meet the top goals in a mid-stage trial, Rigel said in a statement today. The company said it will stop development of the compound as a therapy for allergic asthma.

“This was not the result we expected based on the collection of data we had previously seen with R343 in this therapeutic area,” James Gower, chairman and chief executive officer of Rigel, said in the statement.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.